Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Recurrence

Breast Neoplasms

Breast Diseases

Skin Diseases

Supportive-Expressive Group Therapy plus education

Education

David Spiegel, M.D.

This study will investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic or recurrent breast cancer.

The objective of this study is to investigate the influence of psychosocial treatment on psychological outcomes and survival among women with metastatic/recurrent breast cancer.

Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer

Psychosocial Treatment Effects on Cancer Survival

National Institute of Mental Health (NIMH)

Stanford University

Jack, Lulu & Sam Willson Professor

Disease Attributes

Antineoplastic Agents

All Drugs and Chemicals

Irinotecan

Taxane

Topoisomerase I Inhibitors

Enzyme Inhibitors

Irinotecan monotherapy (trade name: Aili; batches 180103AG \[40 mg\] and 171231AG \[100 mg\]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.

irinotecan

Tao Sun, Doctor

A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade Adverse Events 、overall survival.All the patients will recieve this therapy till disease progress or other occurrence of withdrawal standards.

A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade Adverse Events 、overall survival. irinotecan 100mg/m2,iv,day1,day8,every 3cycles.If no AE happens, increase irinotecan dose to125mg/m2 at the second cycle.All the patients will recieve this therapy till disease progress or other occurrence of withdrawal standards.

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.

Disease Control Rate:Completely Response+Partial Response+Stable Disease

Liaoning Tumor Hospital & Institute

Director of Oncology

Gemcitabine

Paclitaxel

Albumin-Bound Paclitaxel

Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause

Observation for every 12 weeks until disease progression or the date of first documented death from any cause

Li Nanlin, Ph.D

Chen Cong, Master

The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment

2 ml blood sample is needed before enrollment.

Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer

Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer

the time from enrollment to disease progression or the date of first documented death,whichever comes first,to observe the quality of life in participants,assessed up to 3 years

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years

PFS was defined as the time from the date of randomization until the date of disease progression at any site including distant metastasis or second primary tumors or death,assessed up to 3 years

the time from date of randomization until the date of first documented death from any cause,assessed up to 3 years

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer	NCT00226928	Stage IIIB, IV,...	Supportive-Expr... Education	18 Years -	Stanford University
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer	NCT02030678	Stage IIIB, IV,...	irinotecan	18 Years - 65 Years	Liaoning Tumor Hospital & Institute
Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer	NCT02188693	Stage IIIB, IV,... Gemcitabine Maintenance Che...		18 Years - 70 Years	Xijing Hospital
Psychosocial Treatment for Improving Chances of Survival in Women With Breast Cancer	NCT00226928	Stage IIIB, IV,...	Supportive-Expr... Education	18 Years -	Stanford University

Spots Global Cancer Trial Database for stage iiib, iv, recurrent, and metastatic breast cancer